Cerenome secures Florida Blue in-network CNSide CSF test agreement

Cerenome’s CNSide Diagnostics says its first in-network payer agreement with Florida Blue will add CNSide’s CSF molecular profile tests alongside tumor cell enumeration, expanding contracted access to about 164 million covered lives.